MLSS (Milestone Scientific) Intrinsic Value: Projected FCF: $-0.56 (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLSS Milestone Scientific Inc MLSS
37 GF Score
Price $0.50
GF Value $0.60
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Milestone Scientific Intrinsic Value: Projected FCF?

Milestone Scientific MLSS -10.47% 37 Intrinsic Value: Projected FCF is $-0.56 as of Aug. 16, 2026. GuruFocus rates MLSS with a GF Score™ of 37/100 and a GF Value™ of $0.60 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 402 Medical Devices & Instruments companies, Milestone Scientific ranks worse than 248755.97% on this metric.

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2026-08-16), Milestone Scientific's Intrinsic Value: Projected FCF is $-0.56. The stock price of Milestone Scientific is $0.4951. Therefore, Milestone Scientific's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Milestone Scientific's Intrinsic Value: Projected FCF or its related term are showing as below:

MLSS's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.515
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Milestone Scientific  (AMEX:MLSS) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Milestone Scientific's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.4951/-0.5559217906217
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Milestone Scientific Intrinsic Value: Projected FCF Related Terms


Milestone Scientific Intrinsic Value: Projected FCF Historical Data

* Premium members only.

The historical data trend for Milestone Scientific's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Milestone Scientific Intrinsic Value: Projected FCF Chart

Milestone Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.26 -0.38 -0.44 -0.46 -0.51

Milestone Scientific Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.52 -0.52 -0.51 -0.58 -0.56

MLSS vs NEPH, HBIO, POCI: Intrinsic Value: Projected FCF Comparison

For the Medical Instruments & Supplies subindustry, Milestone Scientific's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Milestone Scientific Price-to-Projected-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Milestone Scientific's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Milestone Scientific's Price-to-Projected-FCF falls into.


MLSS
37GF Score
Milestone Scientific Inc MLSS
Intrinsic Value: Projected FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Milestone Scientific Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Milestone Scientific's Free Cash Flow(6 year avg) = $-4.45.

Milestone Scientific's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Jun26)*0.8)/Shares Outstanding (Diluted Average)
=(12.267806016876*-4.4464+3.471*0.8)/93.126
=-0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Intrinsic Value: Projected FCF of $-0.56 mean?
Milestone Scientific (MLSS) has a Intrinsic Value: Projected FCF of $-0.56 as of Aug. 16, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Milestone Scientific and its competitors. According to the industry distribution chart, Milestone Scientific ranks #999999 out of 402 companies in the Medical Devices & Instruments industry.
Is Milestone Scientific's Intrinsic Value: Projected FCF too high?
Milestone Scientific's current Intrinsic Value: Projected FCF is $-0.56. Based on the distribution chart, Milestone Scientific ranks #999999 out of 402 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Milestone Scientific has a GF Score™ of 37/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Milestone Scientific's Intrinsic Value: Projected FCF compare to NEPH and HBIO?
According to the Medical Devices & Instruments industry distribution chart, Milestone Scientific ranks #999999 out of 402 companies for Intrinsic Value: Projected FCF. This places Milestone Scientific in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.52, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Milestone Scientific and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Milestone Scientific's current Intrinsic Value: Projected FCF is $-0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Milestone Scientific stock overvalued right now?
Based on GuruFocus' analysis, Milestone Scientific (MLSS) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.60, compared to a current price of $0.50 — trading 17.5% below its estimated fair value. The current Intrinsic Value: Projected FCF is $-0.56. Milestone Scientific's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Milestone Scientific (MLSS), the current Intrinsic Value: Projected FCF is $-0.56 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Milestone Scientific (MLSS) Overvalued in 2026?

Based on GuruFocus' analysis, Milestone Scientific stock appears to be undervalued. The current stock price of $0.50 is trading 17.5% below its estimated GF Value™ of $0.60. GuruFocus considers Milestone Scientific to be Modestly Undervalued.

Key valuation signals for MLSS:

  • Intrinsic Value: Projected FCF: $-0.56
  • GF Value™: $0.60 vs. price of $0.50 (17.5% below fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the MLSS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Milestone Scientific Business Description

Address 425 Eagle Rock Avenue, Roseland, NJ, USA, 07068
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
37GF Score

Get the complete analysis for MLSS

Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.50
Price
$0.60
GF Value